messag turn strong revenu top consensu
three four busi unit deliv upsid quarter ep beat
follow perform manag reiter cc revenu growth
guidanc rais ep outlook
book updat estim beyond
ep guidanc move higher manag continu forecast full-year sale
growth cc momentum acceler cours year meanwhil
expect earn come cc vs
previous much improv come line howev chang
ebita guidanc interest expens tax expect slightli favor
rel manag last updat vs vs
rais adjust ep estim cc
previous midpoint manag guidanc rang
model call total revenu organ prior
estim turn busi unit cvg forecast essenti flat
growth cardiac rhythm heart failur cc boost strength
coronari structur heart cc slightli moder aortic
peripher vascular cc mitg expect surgic solut revenu
come cc respiratori gastrointestin renal ad
sale cc meanwhil expect rtg growth pace strength brain
therapi cc specialti therapi cc spine
organ pain therapi cc lag behind final
expect diabet revenu come cc full year overal
like backend load year model call growth
rebound roughli first half comp eas
long-term continu tri focu investor attent pipelin
process kick anoth gear unveil compani much-anticip
soft tissu robot surgeri system septemb intrigu find mani
compani key program howev continu see pipelin
stori meantim see stock fairli valu current level given
present state busi maintain neutral rate
sector medic suppli devic
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag includ lead way healthcar landscap shift fee-for-
valu model re-envis mean centuri
devic compani pursu goal deliv econom valu uniqu
combin technolog servic go far beyond tradit purview
med-tech effort mix success date think concept
valu healthcar stay expect fee-for-valu transit play
meantim see execut around compani core financi target
primari driver valu creation front think manag revis
lrp set much achiev bar one could even allow compani deliv
upsid street expect time pipelin matur near-term howev
see stock fairli valu given growth trajectori
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
respect view valuat appropri given medtron
project long-term growth profil top bottom line
respect lag behind broader sector averag approxim
respect better opportun elsewher group view assign
upsid risk rate includ revenu growth exce forecast better-
than-expect execut margin target faster expect shift fee-for-
valu healthcar paradigm benefit compani superior scale play
medtron strength prove disrupt competitor
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
